![Gordon Treadway](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gordon Treadway
Presidente presso Culture Partners
Profilo
Gordon Treadway is currently the President at Culture Partners.
Previously, he worked as the Vice President-Sales at Tercica, Inc. from 2007 to 2014.
He completed his undergraduate degree at Brigham Young University.
Posizioni attive di Gordon Treadway
Società | Posizione | Inizio |
---|---|---|
Culture Partners
![]() Culture Partners Miscellaneous Commercial ServicesCommercial Services Culture Partners engages in the provision of accountability training and consulting services. Its practice areas are accountability, accelerating culture change, employee engagement, execution and implementation, executive team alignment, information technology culture, and leadership development. The company was founded by Roger Connors and Tom Smith in 1989 and is headquartered in Temecula, CA. | Presidente | 01/01/2013 |
Precedenti posizioni note di Gordon Treadway
Società | Posizione | Fine |
---|---|---|
Tercica, Inc.
![]() Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Vendite & Marketing | 03/02/2014 |
Formazione di Gordon Treadway
Brigham Young University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Tercica, Inc.
![]() Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Culture Partners
![]() Culture Partners Miscellaneous Commercial ServicesCommercial Services Culture Partners engages in the provision of accountability training and consulting services. Its practice areas are accountability, accelerating culture change, employee engagement, execution and implementation, executive team alignment, information technology culture, and leadership development. The company was founded by Roger Connors and Tom Smith in 1989 and is headquartered in Temecula, CA. | Commercial Services |
- Borsa valori
- Insiders
- Gordon Treadway